Home
overview
Although the GI drugs market is growing rapidly, at present, there is a distinct lack of targeted drug discovery for many gastrointestinal disorders, with few novel drugs reaching the marketplace.

SMi’s latest Pharmaceuticals conference, ‘Gastrointestinal Drug Development: New & Existing Therapies’ focuses on the challenges faced in gastrointestinal drug development and evaluation. The conference will examine current as well as emerging GI therapies and the strategic development of GI therapeutics to create successful drug portfolios. This conference will make sure that you are kept fully up to date with all the scientific and business news from the field of gastrointestinal drug development.

As you can see from the programme, SMi have strived to, and succeeded in getting expert speakers to discuss these key issues at the conference. These speakers will provide you with valuable insights into how to get the most out of the GI market through their presentations and discussions.

As with all SMi’s Pharmaceutical events, there will also be plenty of networking opportunities available allowing you to discuss the main issues with colleagues from all over the world.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Jörg Täubel

Dr Jörg Täubel, Consultant in Clinical Pharmacology, Charterhouse Clinical Research

9:10 HUMAN TISSUES IN GI RESEARCH

Dr Richard Borman

Dr Richard Borman, Principal Scientist, Pharmagene

  • Use of human tissues in GI research
  • New indications for existing therapeutics
  • Using gene expression studies for target identification
  • Target validation – from gene to function
  • Novel treatments for Irritable Bowel Syndrome
  • Relevance of animal models in GI research
  • 9:40 DRUG DELIVERY

    Dr Verne Cowles

    Dr Verne Cowles, Director, Gastrointestinal Physiology, DepoMed

  • The Gastric Retention (GR) System
  • Improved absorption and bioavailability
  • Advantages of controlled release
  • Reducing gastrointestinal irritation
  • Evaluating the benefits
  • The future of drug delivery
  • 10:20 CREATING A GI PRODUCT PORTFOLIO

    Roly Bufton

    Roly Bufton, Chief Executive, Tillotts Pharma

  • Originator of Asacol, the world leading brand in IBD therapy
  • Colpermin: natural treatment for IBS
  • Purepa: a new, naturally based treatment for Crohn's disease
  • 11:00 Morning Coffee

    11:20 DEVELOPMENT & COMMERCIALISATION OF GI APPLICATIONS

    Dr Peter Meijlink

    Dr Peter Meijlink, General Manager, ForTe

  • The need for strategic product development
  • Improving efficacy
  • Time to market and cost control
  • Effective planning and implementation
  • Managing projects and partnering programmes
  • Future directions
  • 12:00 LEGAL ISSUES IN R & D COLLABORATION AGREEMENTS

    Matthew Warren

    Matthew Warren, Partner, Bristows

  • Legal structures for R & D collaborations
  • Ownership of intellectual property rights
  • Exploitation of intellectual property rights
  • Liability issues
  • Termination
  • 12:40 Networking Lunch

    14:00 THERAPY FOR IBD

    Dr Joseph Tami

    Dr Joseph Tami, Operations Manager, Clinical Development, Isis Pharmaceuticals

  • ISIS 2302
  • Achieving durable remission
  • Evaluating the long-term benefits of ISIS 2302
  • The future of Crohn’s treatments
  • 14:40 INFLAMMATORY BOWEL DISEASE

    Dr Tess Ambrose

    Dr Tess Ambrose, Development Project Manager, KS Buomedix

  • Challenges involved in developing drugs for UC
  • KSB304 – a novel treatment for ulcerative colitis
  • Colonic epithelial protein (CEP) and the inflammatory response in UC
  • Developing dosage at early stages
  • Targeting delivery to the colon
  • Solid dosage form: enabling self administration
  • 15:20 Afternoon Tea

    15:40 NOVEL GI TREATMENTS

    Dr Denis Headon

    Dr Denis Headon, President & Chief Scientific Officer, Agennix

  • Anti-microbial activity
  • Anti-inflammatory activity
  • Clinical studies in the prevention of infection
  • Applications in very low birth weight infants
  • Production of cGMP lactoferrin
  • Future applications
  • 16:20 TREATMENT OF GERD

    Dr Sheldon Sloan

    Dr Sheldon Sloan, Director, GI Medical Development, Department of Medical Affairs, Janssen Pharmaceutica

  • Disease overview
  • Improving control of gastric acidity
  • Therapeutic advances
  • Management of GERD
  • Maintenance of healing
  • Improving patient quality of life
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Hans Graffner

    Dr Hans Graffner, Medical Director, & Vice President, Gastrointestinal Therapy Area, AstraZeneca

    9:10 IMPROVEMENT OF PPI THERAPY

    Dr Tore Lind

    Dr Tore Lind, Medical Director, & Global Product Team Physician, Nexium, AstraZeneca

  • Losec vs Nexium
  • The novel anti-ulcer agent - Nexium
  • Advantages of a single isomer
  • Improved therapy and alternative treatment for acid reflux
  • Gaining regulatory approval
  • Achieving long-term success in the anti-ulcer therapies market
  • 9:40 NOVEL TREATMENTS FOR HELICOBACTER PYLORI INFECTION

    Patrick McLean

    Patrick McLean, Vice Presidet and General Manager - Canada and Europe, Axcan Pharma

  • Current therapeutic treatments for H. pylori infection
  • Triple therapy - advantages
  • Pros and cons of current treatment regimes
  • The clinical need for a H. pylori vaccine
  • The potential of vaccine candidates
  • Future therapies for H. pylori
  • 10:20 DEVELOPING AN EFFECTIVE VACCINE

    Dr Giuseppe Del Giudice

    Dr Giuseppe Del Giudice, Senior Director, Chiron

  • Current issues in vaccine development
  • Strategic planning
  • Improving Helicobacter pylori infection rates
  • A promising approach to eradicating H. pylori
  • A promising approach to prevent H. pylori infection and complications
  • 11:00 Morning Coffee

    11:20 GASTRIC CANCER THERAPIES

    Dr Doriano Fabbro

    Dr Doriano Fabbro, Unit Head, in vitro Lead Profiliing, Novartis Oncology

  • Potential treatment of gastrointestinal stromal tumours
  • Phase I clinical trials as an anti-cancer therapy
  • Acting to reduce tumour size
  • Effective treatments with fewer side-effects
  • Future gastrointestinal anti-cancer therapeutics
  • 12:00 NO-ENHANCED ANTI-ULCERANTS

    Dr Gordon Letts

    Dr Gordon Letts, Chief Scientific Officer & Senior Vice President, Research & Development, NitroMed

  • The potential therapeutic advantage
  • NitRx technology
  • Enhancing the efficacy of existing medicines
  • Advantages of NO-technology
  • The future of gastric ulcer therapies
  • 12:40 Networking Lunch

    14:00 SHORT BOWEL TREATMENTS

    Dr Edward Nemeth

    Dr Edward Nemeth, Chief Scientific Officer, NPS Pharmaceuticals

  • ALX-0600 for gastrointestinal disorders
  • Current development strategies
  • Pilot phase II trial in short bowel syndrome
  • Ways to maximise absorptive area in the intestine
  • Drugs vs surgery
  • Maximising efficacy and minimising side-effects
  • 14:40 GASTROINTESTINAL MOTILITY DISORDERS

    Dr Andrew Sutton

    Dr Andrew Sutton, Partner & Medical Director, Guildford Clinical Pharmacology

  • Gastric motility methods
  • New applications of a non-invasive method
  • Applications of gut transit studies
  • Improving safety profiles of existing drugs as pointers to new drug opportunities
  • 15:20 Afternoon Tea

    15:40 A NEW LOOK AT MOTILIN AGONISTS

    Dr Robert Johnson

    Dr Robert Johnson, Vice President, Medical Affairs & Corporate Development, Kosan Biosciences

  • Current treatments
  • Improving on the early motilides
  • Developing “optimal” motilides at Kosan
  • Reducing tachyphylaxis
  • Fulfilling an unmet medical need
  • 16:20 SPEAKER PANEL

    17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.